Longeveron Inc Ordinary Shares - Class A LGVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.65
- Day Range
- $0.66–0.68
- 52-Week Range
- $0.48–1.80
- Bid/Ask
- $0.67 / $0.68
- Shares Outstanding
- 31.60M
- Market Cap
- $21.33M
- Volume/Avg
- 111,442 / 400,662
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.longeveron.com
Valuation
|
Metric
|
LGVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.21 |
Price/Sales | 10.42 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LGVN
|
|---|---|
Quick Ratio | 3.64 |
Current Ratio | 3.88 |
Interest Coverage | — |
Quick Ratio
LGVN
Profitability
|
Metric
|
LGVN
|
|---|---|
Return on Assets (Normalized) | −121.81% |
Return on Equity (Normalized) | −167.66% |
Return on Invested Capital (Normalized) | −155.07% |
Return on Assets
LGVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?^RJy< | LOCK|>N^^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%gr<&t | LOCK|z#FnX | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!#m?CL | LOCK|w>P | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<d>&#m% | LOCK|?&mP | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Tcd$<$ | LOCK|TZY | $36B | |||
| Moderna Inc
MRNA
| LOCK|Pfs!T< | LOCK|ly | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@@!WQdYt | LOCK|><q^t | $25B | |||
| Incyte Corp
INCY
| LOCK|vzzZy$ | LOCK|<%> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|kh?#<$ | LOCK|>LW | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|dQ?tWZx | LOCK|F! | $17B |
United States